After obtaining these results in psoriasis patients, we next measured IL-19 concentrations in patients with psoriatic arthritis enrolled in the phase 3 ixekizumab trial, SPIRIT-P1, at baseline and after 12 weeks of treatment with ixekizumab and compared the results with PASI scores. Here, IL19 is linked to psoriatic arthritis.